Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 4Triple Negative Breast Neoplasms 3Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rectal Cancer Patients 1Pancreatic Neoplasms 1Locally Advanced Rectal Cancer 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

irinotecan sucrosofate 1camrelizumab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Cancer Patients × camrelizumab × 90 days × Clear all
NCT07521605 2026-04-13

Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer

Guangdong Provincial People's Hospital

Phase 2 Not yet recruiting
44 enrolled
Gastrointestinal

Rectal Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡